<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00450905</url>
  </required_header>
  <id_info>
    <org_study_id>F06001</org_study_id>
    <nct_id>NCT00450905</nct_id>
  </id_info>
  <brief_title>Pain Relief Investigation of Neuromodulation Therapy in an Adult Fibromyalgia Population</brief_title>
  <official_title>Randomized Evaluation of a Low-Frequency Investigational Device Employing Neuromodulation Therapy in Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fralex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PharmaNet</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>McDougall Scientific Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fralex Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being performed to determine the safety and efficacy of Fralex Neuromodulation&#xD;
      Therapy (F-NMT), delivered by the Fralex PRIMA device, in reducing chronic musculoskeletal&#xD;
      pain associated with Fibromyalgia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">December 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically significant pain reduction, evidenced by a statistically significant difference between active and placebo groups in percentage of subjects who achieve a pain reduction of at least 30% at week 12 as compared to the Baseline.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional outcome measures will include mood alteration, sleep quality, improvement of physical functioning and relief medication usage by subjects in both groups.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRIMA Device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic musculoskeletal pain of at least six months duration secondary to&#xD;
             FMS using American College of Rheumatology (ACR) criteria and with the minimum of 11&#xD;
             of 18 defined tender points, measured by dolorimeter at a threshold of up to 4 kg of&#xD;
             pressure&#xD;
&#xD;
          -  Males and females, 18 years and older&#xD;
&#xD;
          -  Able to complete assessment index forms unaided by caregiver/interpreter&#xD;
&#xD;
          -  Pain score of 4 or greater on the Numerical Rating Scale (NRS), averaged from the&#xD;
             Baseline Period scores recorded on the 7 days immediately prior to randomization&#xD;
&#xD;
          -  Demonstration of stabilized pain scores as measured on the NRS during the Baseline&#xD;
             Period (Days -7 to -1)&#xD;
&#xD;
          -  Able to tolerate prohibition of all medications for pain, depression and sleep&#xD;
             disorders except for acetaminophen (up to 4 g/day) and cardiac aspirin (up to 325&#xD;
             mg/day) demonstrated for the Stabilization and Baseline Periods prior to randomization&#xD;
&#xD;
          -  Able and willing to provide a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to sign an informed consent, or to comply with the protocol&#xD;
&#xD;
          -  Evidence of inflammatory rheumatic disease, secondary fibromyalgia, or other severe&#xD;
             painful disorders that might confound assessment of FMS pain&#xD;
&#xD;
          -  Currently under treatment (pharmacological or cognitive therapy) for a Major&#xD;
             Depressive Episode (MDE) or has demonstrated suicidal ideation in the past&#xD;
&#xD;
          -  History or current treatment of migraine, tension or cluster headache requiring&#xD;
             regular medication&#xD;
&#xD;
          -  History or current treatment of seizure disorder&#xD;
&#xD;
          -  History or current treatment of cancer with the exception of basal cell carcinoma and&#xD;
             cervical dysplasia&#xD;
&#xD;
          -  Cognitive dysfunction or personality disorder which would preclude self-directed&#xD;
             treatment, self assessment and / or diary completion&#xD;
&#xD;
          -  Clinically significant or unstable medical or psychological conditions that, in the&#xD;
             opinion of the investigator, would compromise participation&#xD;
&#xD;
          -  Hearing aids, metal implants (excludes dental work) above mid torso or in the cranium&#xD;
             (e.g. plates, implants or clips). (Metal implants in parts of the body below&#xD;
             mid-torso, such as knee or hips replacements, clips, screws or plates to stabilize&#xD;
             fractures are acceptable)&#xD;
&#xD;
          -  Pacemakers, defibrillators, implanted neurostimulators, implanted drug pumps or other&#xD;
             electrical implanted devices&#xD;
&#xD;
          -  Insufficient knowledge of English to complete the self-assessment forms&#xD;
&#xD;
          -  History of or current drug or alcohol abuse&#xD;
&#xD;
          -  History of abuse of a previous physician relationship or the medical system&#xD;
&#xD;
          -  Receiving disability insurance, applying for disability insurance, or engaged in&#xD;
             litigation related to FMS&#xD;
&#xD;
          -  Use of an investigational drug or device in a controlled study within 30 days&#xD;
&#xD;
          -  Pregnancy (U.S. sites only)&#xD;
&#xD;
          -  Breastfeeding or intending to breastfeed (U.S. sites only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmdale</city>
        <state>California</state>
        <zip>93550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642-8604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2N 6K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2007</study_first_posted>
  <last_update_submitted>October 3, 2008</last_update_submitted>
  <last_update_submitted_qc>October 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2008</last_update_posted>
  <keyword>Chronic musculoskeletal pain secondary to Fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

